il8

HuMax-IL8 (MDX 018) is a humanized anti-IL-8 monoclonal antibody for the study of metastatic or unresectable solid tumors.

N'-Nitro-D-arginine (N'-Nitro-D-arginine) is a Building Block.

ABX-IL8 is a humanized antibody targeting IL-8, which interferes with the tubular formation of human umbilical vein endothelial cells, inhibiting angiogenesis, tumor growth, and metastasis in human melanoma.

Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

2-Benzothiazolamine (2-ABT) is a nitrogen-containing heterocyclic compound used as a reaction intermediate in the synthesis of a variety of drugs. It inhibits cytochrome P450 activity and has also shown anti-inflammatory, anticonvulsant and anticancer activities in animal models.

Liranaftate (Piritetrate) is a thiocarbamate and squalene epoxidase inhibitor with antifungal activity. Liranaftate inhibits fungal squalene epoxidase, an enzyme that plays a key role in the synthesis of sterol which is essential for cell membrane integrity. By preventing ergosterol synthesis and causing accumulation of squalene, this agent increases cell membrane permeability, cell leakage and eventually cell lysis.

Fenamic acid (N-Phenylanthranilic acid) is a chloride channel blocker that causes renal papillary necrosis in rats. Fenamic acid serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including flufenamic acid, tolfenamic acid, mefenamic acid, and meclofenamic acid.

6-OAU (GTPL5846)(GTPL5846; 6-n-octylaminouracil) is a surrogate agonist of GPR84; activates human GPR84 in the presence of Gqi5 chimera in HEK293 cells with an EC50 of 105 nM in the PI assay.

AF 12198 Acetate is a novel low molecular weight antagonist of IL-1

R112 is an ATP-competitive inhibitor of Syk kinase. Ki=6 nM,IC50=226 nM.

GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor that inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells[1]. It blocks the synergy between NOD2 and TLR2 without affecting NOD1, TNFR1, and TLR2-mediated responses. At 5 μM, GSK717 inhibits the release of IL-8, IL-6, TNFα, and IL-1β in primary human monocytes stimulated with MDP[1]. [1]. Rickard DJ, et al. Identification of benzimidazole diamides as selective inhibitors of the nucleotide-binding oligomerization domain 2 (NOD2) signaling pathway. PLoS One. 2013;8(8):e69619. Published 2013 Aug 1.

1. Berberrubine chloride (9-Berberoline Chloride) has antitumor activity. 2. Berberrubine has antidiabetic activity. 3. Berberrubine dose-dependently inhibits IL-8 and MCP-1 protein levels in the media and mRNA expression of the cells stimulated with IL-1beta or TNF-alpha.

Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta converting enzyme.

E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.

Isoforskolin is derived from Coleus forskohlii and reduces the secretion of TNF-α, IL-1β, IL-6 and IL-8 in human mononuclear leukocytes. Isoforskolin can be used in studies about the treatment of Lyme arthritis.

Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC50: 1 nM). Remibrutinib has the potential for Chronic urticaria (CU) treatment.

AZD8797 (KAND567) is an orally available, selective and potent human CX3CR1-converting antagonist with inhibitory effects on CX3CR1 and CXCR2, and potentially protects against SARS-CoV-2-induced neuronal damage, preventing worsening of nociceptive sensitization and microglial activation in a migraine model of rats following seizures.

LC-04-045 is a molecular glue degrader (MGD) of NEK7 (NIMA related kinase 7). This compound effectively degrades NEK7 in MOLT-4 cells, exhibiting a DC50 (half-maximal degradation concentration) of 7 nM and a Dmax (maximum degradation rate) of 90%. LC-04-045 displays high selectivity for NEK7 across the proteome and mediates NEK7 degradation via the ubiquitin-proteasome system (UPS), relying on a degradation motif that includes glycine 57 (G57) in NEK7. Additionally, LC-04-045 effectively inhibits the secretion of IL-1β and IL-18, with IC50 values of 33.03 nM and 32.99 nM, respectively. LC-04-045 is applicable for research in inflammatory diseases.

GSK-345931A (compound 3) is a potent and orally active RIP2 (receptor interacting protein 2) inhibitor that suppresses production of multiple pro-inflammatory cytokines, suitable for studying autoimmune diseases.

CP-467688 is a bio-active chemical.

Interleukin-8 (IL-8) (54-72), a peptide comprising amino acids 54-72 from the mature IL-8 sequence and 81-99 from the pre-processed form, inhibits the flow-based adhesion of primary human neutrophils to human umbilical vein endothelial cells (HUVECs).

Anti-CXCL8/IL-8 Antibody is a humanized monoclonal antibody targeting the chemokine CXCL8 (Interleukin-8, IL-8). CXCL8 is a pro-inflammatory chemokine frequently overexpressed in the tumor microenvironment, which promotes tumor angiogenesis, survival, proliferation, and migration by binding to its G protein-coupled receptors, CXCR1 and CXCR2. This antibody effectively neutralizes extracellular CXCL8, blocking its interaction with CXCR1/2 and subsequently disrupting the paracrine and autocrine signaling loops driven by CXCL8. This mechanism inhibits tumor-associated vascularization and diminishes tumor cell resistance to conventional therapies, making it a critical tool for researching solid tumor progression, metastasis, and microenvironmental modulation.

CAT-2200 is a human monoclonal antibody (IgG1/lambda) targeting Interleukin-17A (IL-17A/CTLA-8). IL-17A is a critical pro-inflammatory cytokine produced by Th17 cells, playing a central role in the pathology of autoimmune diseases such as psoriasis, rheumatoid arthritis, and multiple sclerosis. CAT-2200 specifically binds to the IL-17A homodimer, blocking its interaction with cell surface receptors (IL-17RA/IL-17RC), thereby effectively neutralizing the biological activity of IL-17A. Studies demonstrate that CAT-2200 significantly inhibits the IL-17A-induced release of downstream inflammatory mediators (e.g., IL-6, IL-8, and GRO-alpha). This antibody is frequently used as a tool antibody or positive control for researching the IL-17A signaling pathway and its role in inflammatory responses.

CXCL8 (54-72) is a C-terminal peptide segment of the chemokine CXCL8. This peptide features a long, highly positively charged C-terminal region that interacts with the negative charges on glycosaminoglycans (GAG) to facilitate binding. CXCL8 (54-72) inhibits neutrophil adhesion and migration, as well as adhesion to endothelial cells. It is useful in studying the role of chemokines in inflammatory responses.